Accessing biopharma innovation in China

China has rapidly evolved from a supporting player to a central force in global biopharma innovation. Fueled by government initiatives, regulatory reforms, and cutting-edge infrastructure, the country now offers a dynamic ecosystem for drug development and deal-making. With accelerated approvals, R&D incentives, and growing cross-border collaboration, China presents unique opportunities, alongside regulatory and geopolitical complexities, that global pharma cannot ignore.

This report explores:

• Market Foundations: How regulatory shifts and innovation hubs are shaping China’s biopharma landscape.
• Innovation Trends: Growth in advanced modalities, first-in-class launches, and diverse therapeutic areas.
• Deal-Making Dynamics: Rising licensing activity and evolving partnership models.
• Winning Strategies: Practical approaches to access innovation while balancing risk, speed, and control.
• Lessons Learned: Key watchouts and enablers for success in China’s fast-changing environment.

Engaging with China’s ecosystem is no longer optional, it’s a strategic imperative. Companies that act early, build trusted partnerships, and align global and local strategies will unlock new opportunities and help define the next era of biopharma innovation.